Polsinelli Lands Landmon as Hatch-Waxman and Biologics Chair

Chad Landmon has joined Polsinelli as a shareholder and chair of the firm’s Hatch-Waxman & Biologics practice in Washington, the firm said Tuesday.

Landmon guides clients through clearing both Hatch-Waxman pharmaceutical and biologics patent litigation and Food and Drug Administration approval hurdles, according to the firm.

He has represented manufacturers of pharmaceuticals, biologics, medical devices and human tissue products with billions of dollars in annual sales, and has litigated more than 60 cases in the past decade, the firm said.

This story was produced by Bloomberg Law Automation.